Included in the formulation
АТХ:S.01.B.C Non-steroidal anti-inflammatory drugs (NSAIDs)
S.01.B.C.10 Nepafenac
Pharmacodynamics:Prodrug. It penetrates through the cornea and hydrolyses to an active form - amfenac. Amfenac inhibits prostaglandin H-synthase, an enzyme involved in the synthesis of prostaglandins.
Has anti-inflammatory, analgesic effect.
Pharmacokinetics:Used for topical application - no systemic effect.
Indications:It is used for cataracts, eye pain, for the prevention and treatment of postoperative inflammation after cataract removal.
VII.H25-H28.H26.9 Cataract, unspecified
VII.H55-H59.H57.1 Eye Pain
Contraindications:Children up to 10 years. Individual intolerance to non-steroidal anti-inflammatory drugs.
Carefully:Individual sensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. It is used with caution during pregnancy and lactation.
Dosing and Administration:1 drop 3 times a day in the conjunctival sac the day before the surgery and within 2 weeks after the operation.
The highest daily dose: 6 drops.
The highest single dose: 1 drop.
Side effects:The system of hematopoiesis: possibly an increase in bleeding time.
Local reactions: development of keratitis, slowing of healing after surgery.
Allergic reactions.
Interaction:Clinically significant interactions are not described.
Special instructions:During the treatment, contact lenses are not recommended. When using other ophthalmic agents for topical application, it is recommended to maintain the interval for 5 minutes.